Ensayo clínico aleatorizado de tres pautas de quimioprofilaxis para prevenir la tuberculosis en pacientes infectados por el VIH con anergia cutánea

Rivero, Antonio; López-Cortés, Luis; Castillo, Rafael; Lozano, Fernando; García, Miguel Ángel; Díez, Felipe; Escribano, José Carlos; Canueto, Jesús; Pasquau, Juan; Hernánde, Juan José; Polo, Rosa; Martínez-Marcos, Francisco Javier; Kindelán, José María; Rey, Rafael; "Grupo Andaluz para el estudio de las Enfermedades Infecciosas (GAEI.
Enferm. infecc. microbiol. clín. (Ed. impr.) ; 21(6): 287-292, jun. 2003.
Artigo Es | IBECS (Espanha) | ID: ibc-24967

Documentos relacionados

  1. Pharmacokinetics of rifampicin, isoniazid & pyrazinamide during daily & intermittent dosing: A preliminary study.
  2. Optimising pyrazinamide for the treatment of tuberculosis.
  3. Clinical impact of plasma concentrations of first-line antituberculosis drugs.
  4. Altered drug exposures of first-line TB drugs in a moxifloxacin-containing treatment regimen.
  5. Evaluation of pharmacokinetic-pharmacodynamic relationships and selection of drug combinations for tuberculosis.
  6. Treatment Strategy for Rifampin-Susceptible Tuberculosis.
  7. Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study.
  8. Analysis of Adverse Drug Reactions to First-Line Anti-Tuberculosis Drugs Using the Korea Adverse Event Reporting System.
  9. Intrapulmonary Pharmacokinetics of First-line Anti-tuberculosis Drugs in Malawian Patients With Tuberculosis.
  10. Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg<sup>-1</sup> rifampicin.